Perfect Medical Health Management Limited Overview
Perfect Medical is a founder-controlled, Hong Kong-centred operator of non-invasive aesthetic medical centres. Around its core aesthetic medical business it has built a set of non-aesthetic "health management" services: hair growth, pain management, snoring treatment, and Japanese-style sleep therapy under the "Goku Spa" brand.
Hong Kong generates about 80% of revenue. The rest comes from Mainland China (Beijing, Shanghai, Guangzhou, Shenzhen), Macau, Australia (Sydney, Melbourne) and Singapore.
The business model is cash-rich and asset-light. Customers prepay treatment packages, the company carries no bank debt, and it has paid out 100% or more of its profits as dividends for eleven consecutive years.
Revenue peaked at HK$1.39bn in FY2023–FY2024. It has since fallen 31% as Hong Kong consumers shifted spending to Shenzhen and South Korea. Management has responded by consolidating stores, cutting headcount by 38% from FY2023 to FY2026, deploying AI-driven marketing, and pursuing a multi-brand strategy that includes the Korean dermatology brand "Oracle".
Company's own description
The annual report describes the company itself as an investment holding company. Its subsidiaries provide medical and aesthetic medical services. [S1]
The FY2025/26 report sets out a mission with four parts:
-
the best customer service and experience;
-
maximum returns for shareholders;
-
empowering employees;
-
social responsibility.
It also names five pillars under the banner of maintaining sustainable growth:
-
(i) aesthetic and non-aesthetic service offerings (pain management, hair growth, sleep therapy);
-
(ii) high value-for-money Korean medical beauty services;
-
(iii) cross-selling within an ecosystem;
-
(iv) AI-driven marketing;
-
(v) operational efficiency and cost control. [S1]
Management describes "4 major business sectors": Aesthetic Medical, Hair Growth, Pain Management and Sleep Therapy. [S2, S3]
Independent characterisation
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Avg spending per client, aesthetic medical (HK$) | 28,026 | 28,784 | — | — |
| Avg spending per client, non-aesthetic medical (HK$) | 14,378 | 15,666 | — | — |
| Avg customer spending excl. promotional packages, alternative definition (HK$) | — | 54,000 | 47,000 | — |
| Aesthetic medical share of sales contracts (%) | — | 81.8 | — | — |
| Total leased service area ('000 sq ft) | — | 304 | 279 | 243 |
Economically, Perfect Medical is a prepaid consumer-services retailer with a medical licence wrapper.
How revenue is earned: Customers sign "sales contracts" for treatment packages, usually prepaid and sometimes paid by instalment or credit card. The company holds this cash and recognises revenue as treatments are delivered. Sales contracts were HK$1,446.4m in FY2024, against revenue of HK$1,393.3m. [S3]
What drives margins: The main levers are therapist utilisation, rent per square foot, and marketing cost per customer acquired.
Payment arrangements: Some credit-card and instalment facilities are secured by pledged bank deposits. [S1]
Revenue model mix. About 100% of revenue is service-based (treatments). Product sales have been a minor complement since 2004. There is no material subscription or licensing income. Membership and package prepayment work in a similar way to a subscription, but are recognised on delivery.
Value chain position. The company is a downstream, self-operated service provider. It buys equipment and consumables from device and consumable vendors. Supplier concentration is high: in FY2026 the top five suppliers accounted for 78.81% of purchases and the largest single supplier for 57.23%. [S1]
Customers. The customer base is retail consumers, mostly women, in the mid-to-high-end bracket. Customer concentration is negligible: the top five customers were 0.92% of FY2026 sales. [S1] The workforce is also predominantly female, with a women-to-men ratio of 716:71 at 31 March 2026. [S1]
End-markets served:
-
non-invasive medical aesthetics (energy-based devices, injectables, skin treatments);
-
hair-loss treatment;
-
musculoskeletal pain management;
-
sleep and stress therapy;
-
snoring treatment;
-
Korean-style dermatology (via "Oracle").
Key operating metrics disclosed
Sources: [S1, S2, S3]. The two average-spend series use different definitions. The FY2025 AR's HK$54,000 figure for FY2024 does not reconcile with the FY2024 AR's HK$28,784. No average-spend metric was disclosed for FY2026. The FY2026 total service area is derived from 145,000 sq ft in Hong Kong plus 98,000 sq ft outside Hong Kong.
Strategy
Stated strategic themes (paraphrased from AR FY2025/26 and AR FY2024/25)
-
Premiumisation over price competition. Protect margins through brand equity and customer experience rather than discounting. [S1]
-
Multi-brand ecosystem. Strengthen "Perfect Medical" and "New Beauty", and scale high-potential concepts such as Oracle and Goku Spa to reach different demographics. [S1]
-
Non-aesthetic services as entry points. Use pain, hair, sleep and snoring services as low-friction acquisition channels that cross-sell into higher-margin aesthetics. [S1]
-
AI and digital transformation. Apply AI across marketing, CRM and operations to lower customer acquisition cost, raise retention and automate administration. [S1, S2]
-
Network optimisation. A two-phase plan: rightsizing in H1 FY2026, then stabilisation and same-store productivity. [S1]
-
Financial discipline and shareholder returns. Zero bank debt and a sustainable dividend policy. The formal policy has no fixed payout ratio, but the track record is 100% or more for 11 years. [S1]
-
Geographic posture.
-
Hong Kong: core.
-
PRC: defensive and focused on premium cities.
-
Australia and Singapore: optimise for cash flow. [S1]
-
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Timing | Status / target |
|---|---|---|
| Cost-optimisation programme: headcount, lease renegotiations, store consolidation | H2 FY2025 – H1 FY2026 | Headcount cut by 302 against the FY2024 baseline (FY2025), then to 787 (FY2026). Key costs down 15.4% in FY2026. [S1, S2] |
| Oracle exclusive HK cooperation (Korean dermatology) | Signed Q1 FY2026 | Rolled out in FY2026; management says it reached younger clients. No revenue disclosed. [S1] |
| Goku Spa PRC expansion | H2 FY2025 | Entered South and East China; losses narrowing (FY2025). [S2] |
| Shenzhen clinic M&A pipeline | Announced in AR FY2025 (June 2025) | Seeking high-potential medical beauty clinics in Shenzhen to capture cross-border demand. No acquisition completed as of AR FY2026. [S1, S2] |
| AI-driven marketing and CRM | FY2024 onward | Marketing spend down 16.5% in FY2026 while sales momentum improved in H2. [S1] |
| Value-driven packages and flexible instalment plans | FY2026 | Deployed to defend traffic. [S1] |
| Snoring treatment launch | FY2026 | Operational. [S1] |
| 2026 Share Option Scheme and 50m-option grant to CEO | Apr–Jun 2026 | Approved 18 June 2026. [S1] |
| ESG: green deposits | FY2023–FY2024 | HK$214.0m (FY2023) and HK$265.9m (FY2024) placed in bank green deposits. [S3, S4] |
Medium-term targets and guidance
No quantitative medium-term targets: (revenue, margin or store count) have been published.
-
Qualitative guidance (AR FY2026, 30 June 2026):
-
momentum continued into early FY2027, with "encouraging" April and May 2026;
-
measured growth;
-
selective multi-brand expansion;
-
exploring strategic opportunities. [S1]
-
-
AR FY2025 said the Oracle plus Shenzhen M&A "dual-track" strategy would underpin profit growth "over the next five years", without numbers. [S2]
Products & Services
Pricing is package-based and is not publicly disclosed at list-price level. The only available proxies are average spending per client.
Aesthetic medical (core; about 82% of sales contracts in FY2024)
| Offering / brand | Description | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Perfect Medical (flagship brand) | Non-invasive medical aesthetics delivered in flagship "mega centres" and residential shops: energy-based device treatments for skin rejuvenation, tightening and body contouring, and injectables. Specific devices are not itemised in the reviewed sources. | Mid-to-high-end HK and cross-border clients | Brand since 2021 rename; flagship model since 2013 | Flagships in Mong Kok (Langham Place), Causeway Bay, Tsim Sha Tsui, Admiralty [S2, S3] |
| New Beauty | A second core brand named in the FY2026 outlook as a flagship alongside "Perfect Medical". Its specific positioning is not described. | — | — | [S1] |
| Oracle (exclusive HK partnership) | A premium Korean medical beauty concept led by dermatologists, with Korean fashion-style elements, positioned as high value-for-money. | Younger demographic; value-seeking clients who might otherwise travel to Korea | Agreement Q1 FY2026; rollout during FY2026 | Management says it broadened the customer base to younger clients [S1, S2] |
| Dr Face (historical) | Earlier medical beauty brand: injectables (Botox, Restylane, Sculptra) and lasers (hair removal, rejuvenation, depigmentation) | Not applicable | Pre-2021 | — |
| Perfect Shape 必瘦站 (legacy) | Original slimming and beauty brand | Not applicable | 2,003 | Replaced by Perfect Medical branding in 2021 [S7, S9] |
Non-aesthetic medical / health management
| Offering | Description | Launch | Notes |
|---|---|---|---|
| Pain management | Specialist pain-treatment medical centres combined with aesthetics | First centre 30 Nov 2020 | A model branch generated HK$44.8m of contracts in 60 business days [S18] |
| Hair growth | Hair-loss and regrowth treatment programmes | Around FY2021–FY2022 | One of the "4 major business sectors" [S3] |
| Goku Spa (sleep therapy) | Japanese head-therapy techniques aimed at stress, anxiety and poor sleep. Run as a JV/cooperation with a Japanese luxury brand. | Jan 2024 (HK, 7 locations by Mar 2024); South and East China entry in H2 FY2025 | Loss-making in FY2025, with losses "narrowing significantly" [S2, S3] |
| Snoring treatment | Specialised treatment line | First named in AR FY2026 | Described as a low-friction entry point for new members [S1] |
| Product sales | Skincare and slimming products complementing services | Since 2004 | Immaterial [S9] |
Store formats
| Format | Description | Since |
|---|---|---|
| Flagship / mega centre | Large multi-service hubs that centralise personnel and equipment | 2013 [S3] |
| Residential shop | Smaller, lower-capex neighbourhood shops feeding flagship centres ("Dual-Circulation") | June 2023 [S3] |
| Concept store | Device-focused stores. Each reportedly cost about HK$5–6m in capex and broke even in about 6 weeks (from a chairman interview). | Yuen Long, Taikoo Shing [S18] |
Financial Narrative
Income statement — chartable
Sources: [S1–S5]. Gross profit is not reported, because the company presents expenses by nature. One aggregator shows FY2025 "gross profit" of HK$701.2m (62.2%) on its own definition [S12]; this is not a company figure.
Margins — chartable
FY2022 EBITDA and operating margins are derived; the other figures are company-reported. [S1–S5]
Revenue CAGR (derived):
-
FY2022→FY2026: −8.1% a year.
-
FY2020 (HK$1,241.0m)→FY2026: −4.2% a year.
-
FY2012 (HK$381.2m)→FY2026: +6.8% a year. [S3, S9]
Longer history (context) — chartable
Sources: [S2, S3, S6]
Cost structure — chartable
Sources: [S1, S2, S3]. FY2025 figures are as restated in AR FY2026. Percentages are derived.
Balance sheet — chartable
Sources: [S1–S5]. The FY2022 cash figure is "cash and cash equivalents". Financial investments are those listed in the MD&A "significant investments" table: listed equities, plus from FY2026 US ETFs and bank unit trusts. FY2026 total = HK$80.3m listed equities + HK$77.9m ETFs + HK$70.2m unit trusts.
Cash flow — chartable
Sources: [S1–S5]. FCF and dividends declared are derived.
Share capital fell slightly from HK$125.653m (FY2023) to HK$125.619m (FY2024), which implies a small repurchase of about 0.34m shares in FY2024. Its value was not disclosed in the reviewed sources.
Ratios — chartable
Sources: [S1–S5]. FY2022 ROE is derived; the FY2022 ROA of 23.8% is as reported in AR 2023. Total liabilities/equity, asset turnover and net debt/EBITDA are derived. The FY2022 current ratio was below 1.0, as the company reported net current liabilities of HK$14.8m.
The following were not disclosed:
ROIC: It is not meaningful on standard definitions, because invested capital ex-cash is close to zero or negative (deferred revenue funds working capital).
Cash conversion cycle: It is not meaningful for a prepaid-services model.
Commentary on trends, inflections and drivers
Plateau (FY2022–FY2024).
-
Revenue stalled at about HK$1.35–1.39bn after the FY2022 post-COVID rebound (+23.9%).
-
FY2023 profit included one-off HK government Employment Support Scheme subsidies. Excluding them, FY2024 profit grew 6.8%. [S3]
-
Margins were stable: net margin about 22.6–22.7%.
-
Dividends ran ahead of earnings (payouts of 118.6% and 125.5%), which drew down cash from HK$656.8m to HK$575.3m.
Inflection (FY2025).
-
Revenue fell 19.1% and profit fell 34.5%.
-
Management blamed weak HK consumer confidence and HK residents seeking cheaper aesthetic treatments in Shenzhen and South Korea. HK retail sales fell 7.3% in 2024. [S2]
-
Fixed costs (staff and rent) did not flex fast enough, so EBITDA margin fell almost 5 percentage points to 28.3%.
-
The worst half was H2 FY2025, with a net margin of 13.0%.
Rightsizing (FY2026).
-
Headcount fell from 971 to 787 (−19%; −40% from 1,317 at FY2023).
-
Leased area fell from 279k to 243k sq ft.
-
Marketing spend fell 16.5% and rent-related costs fell 10.8%.
-
Total key costs fell 15.4%, slightly more than the 14.7% revenue decline, so operating margin held at 22.1% and net margin improved to 18.6%.
Structural observations.
-
The business generates exceptional ROE (46–64%), because equity is deliberately kept small through more-than-100% payouts and customer prepayments fund working capital.
-
The equity base has stopped shrinking (HK$387.9m in FY2026 against HK$378.7m in FY2025), but cash keeps falling. Some cash has been redeployed into a HK$228m investment portfolio that now includes US tech stocks and ETFs. This raises capital-allocation questions.
-
The working-capital cushion has thinned. Net current assets fell from HK$231.5m (FY2023) to HK$20.1m (FY2026), and the current ratio from 1.44x to 1.06x. Continued over-100% payouts will be harder to sustain without earnings growth.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong revenue (HKD Mn) | 975.1 | 1,040.1 | 1,081.4 | 893.8 | 765.6 |
Outside Hong Kong revenue (HKD Mn) | 374.9 | 349.2 | 311.9 | 234.1 | 196.8 |
Total revenue (HKD Mn) | 1,350.0 | 1,389.3 | 1,393.3 | 1,127.9 | 962.3 |
Hong Kong share of revenue (%) | 72.2 | 74.9 | 77.6 | 79.2 | 79.6 |
Outside HK share of revenue (%) | 27.8 | 25.1 | 22.4 | 20.8 | 20.4 |
Hong Kong revenue YoY growth (%) | — | 6.7 | 4.0 | -17.3 | -14.3 |
Outside HK revenue YoY growth (%) | — | -6.9 | -10.7 | -24.9 | -15.9 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | H1FY2023 | H2FY2023 | H1FY2024 | H2FY2024 | H1FY2025 | H2FY2025 | H1FY2026 | H2FY2026 |
|---|---|---|---|---|---|---|---|---|
Revenue (HKD Mn) | 668.3 | 721.0 | 718.1 | 675.2 | 620.3 | 507.6 | 485.9 | 476.4 |
Profit attributable (HKD Mn) | 150.7 | 164.9 | 166.4 | 149.4 | 140.8 | 66.0 | 94.8 | 83.9 |
Net margin (%) | 22.5 | 22.9 | 23.2 | 22.1 | 22.7 | 13.0 | 19.5 | 17.6 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 1,350.0 | 1,389.3 | 1,393.3 | 1,127.9 | 962.3 |
Revenue YoY growth (%) | 23.9 | 2.9 | 0.3 | -19.1 | -14.7 |
EBITDA, company definition (HKD Mn) | 469.5 | 482.3 | 461.3 | 319.1 | 268.5 |
Operating profit (HKD Mn) | 392.5 | 396.1 | 382.4 | 251.6 | 213.0 |
Profit before tax (HKD Mn) | — | 391.5 | 383.7 | 252.5 | 211.2 |
Profit attributable to equity holders (HKD Mn) | 305.2 | 315.6 | 315.8 | 206.9 | 178.7 |
EPS basic (HK cents) | 24.8 | 25.3 | 25.1 | 16.5 | 14.2 |
EPS diluted (HK cents) | 24.8 | 25.3 | 25.1 | 16.5 | 14.2 |
Dividend per share, total (HK cents) | 24.8 | 30.0 | 31.5 | 16.6 | 14.6 |
Dividend payout ratio (%) | 100.0 | 118.6 | 125.5 | 100.6 | 102.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin (%) | 34.8 | 34.7 | 33.1 | 28.3 | 27.9 |
Operating margin (%) | 29.1 | 28.5 | 27.4 | 22.3 | 22.1 |
Net margin (%) | 22.6 | 22.7 | 22.7 | 18.3 | 18.6 |
Income Statement and Per-Share Data
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|
Revenue (HKD Mn) | 1,241.0 | 1,089.8 | 1,350.0 | 1,389.3 | 1,393.3 | 1,127.9 | 962.3 |
Operating profit (HKD Mn) | 456.2 | 365.9 | 392.5 | 396.1 | 382.4 | 251.6 | 213.0 |
Profit attributable (HKD Mn) | 360.2 | 284.6 | 305.2 | 315.6 | 315.8 | 206.9 | 178.7 |
EPS basic (HK cents) | 32.2 | 24.3 | 24.8 | 25.3 | 25.1 | 16.5 | 14.2 |
DPS total (HK cents) | 34.0 | 38.0 | 24.8 | 30.0 | 31.5 | 16.6 | 14.6 |
Income Statement
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Cost of inventories & consumables (HKD Mn) | 32.5 | 27.6 | 17.8 | 21.0 |
Employee benefit expenses (HKD Mn) | 470.6 | 471.7 | 408.9 | 333.7 |
Marketing expenses (HKD Mn) | 150.8 | 159.6 | 140.3 | 117.2 |
Depreciation of PP&E (HKD Mn) | 86.3 | 78.9 | 67.5 | 55.5 |
Rental lease related expenses (HKD Mn) | 174.0 | 165.1 | 147.9 | 132.0 |
Other operating expenses (HKD Mn) | 118.8 | 126.2 | 108.5 | 94.7 |
Total key costs (HKD Mn) | 1,033.0 | 1,029.0 | 890.9 | 754.0 |
Employee costs as % of revenue | 33.9 | 33.9 | 36.3 | 34.7 |
Rent-related costs as % of revenue | 12.5 | 11.8 | 13.1 | 13.7 |
Marketing as % of revenue | 10.9 | 11.5 | 12.4 | 12.2 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 1,281.2 | 1,296.3 | 1,221.8 | 935.9 | 834.2 |
Total liabilities (HKD Mn) | 786.9 | 684.0 | 725.0 | 557.2 | 446.3 |
Total equity (HKD Mn) | 494.3 | 612.3 | 496.8 | 378.7 | 387.9 |
Cash & bank balances (HKD Mn) | 444.6 | 656.8 | 575.3 | 394.6 | 294.9 |
Bank borrowings (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt excl. leases (HKD Mn) | -444.6 | -656.8 | -575.3 | -394.6 | -294.9 |
Net current assets (HKD Mn) | -14.8 | 231.5 | 180.3 | 72.4 | 20.1 |
Financial investments at fair value (HKD Mn) | — | 81.0 | 59.7 | 95.5 | 228.4 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net cash from operating activities (HKD Mn) | 513.9 | 560.6 | 497.1 | 332.9 | 339.5 |
Capital expenditure (HKD Mn) | — | — | 50.1 | 33.5 | 24.6 |
Free cash flow, OCF minus capex (HKD Mn) | — | — | 447.0 | 299.4 | 314.9 |
Dividends declared, derived DPS x shares (HKD Mn) | 307 | 377 | 396 | 209 | 183 |
Share buybacks (HKD Mn) | — | — | — | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, company (%) | 61.8 | 51.6 | 63.6 | 54.5 | 45.9 |
ROA, company (%) | 23.8 | 24.3 | 25.8 | 22.1 | 21.4 |
Current ratio (x) | — | 1.44 | 1.35 | 1.18 | 1.06 |
Bank debt / equity (x) | 0 | 0 | 0 | 0 | 0 |
Total liabilities / equity (x) | 1.59 | 1.12 | 1.46 | 1.47 | 1.15 |
Asset turnover, revenue / total assets (x) | 1.05 | 1.07 | 1.14 | 1.21 | 1.15 |
Net debt / EBITDA excl. leases (x) | -0.95 | -1.36 | -1.25 | -1.24 | -1.10 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong (HKD Mn) | 975.1 | 1,040.1 | 1,081.4 | 893.8 | 765.6 |
Mainland China + Macau + Australia + Singapore (HKD Mn) | 374.9 | 349.2 | 311.9 | 234.1 | 196.8 |
Hong Kong YoY growth (%) | — | 6.7 | 4.0 | -17.3 | -14.3 |
Outside HK YoY growth (%) | — | -6.9 | -10.7 | -24.9 | -15.9 |
Revenue by Region
| Region | H1FY2023 | H1FY2024 | H1FY2026 |
|---|---|---|---|
Hong Kong revenue (HKD Mn) | 492.4 | 549.6 | 386.8 |
Outside HK revenue (HKD Mn) | 175.9 | 168.5 | 99.0 |
Share Price & Returns
| Period | Return (%) | Start price (HKD) |
|---|---|---|
3 months | 15.65 | 1.15 |
Year to date 2026 | 7.26 | 1.24 |
1 year | -15.29 | 1.57 |
3 years | -65.90 | 3.90 |
5 years | -79.73 | 6.56 |
Since IPO (adjusted) | 530.45 | 0.21 |
Valuation Multiples
| Multiple | Perfect Medical | Basis |
|---|---|---|
Market cap (HKD Mn) | 1,671 | 1,256.2m shares x HK$1.33 |
P/E (x) | 9.4 | 1.33 / 0.142 |
Dividend yield (%) | 11.0 | 14.6c / HK$1.33 |
P/B (x) | 4.3 | 1,671 / 387.9 |
EV, ex-leases, net of cash and investments (HKD Mn) | 1,148 | 1,671 − 294.9 − 228.4 |
EV/EBITDA (x) | 4.3 | Company post-rent EBITDA of 268.5 |
EV/Sales (x) | 1.19 | Revenue 962.3 |
EC Healthcare P/S (x), peer | 0.12 | Market cap about 450 / revenue 3,770.2 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim DPS (HK cents) | 17.7 | 13.0 | 13.2 | 11.2 | 7.6 |
Special DPS, all specials in year (HK cents) | 0 | 4.7 | 6.4 | 0.1 | 0 |
Final DPS (HK cents) | 7.1 | 12.3 | 11.9 | 5.3 | 7.0 |
Total DPS (HK cents) | 24.8 | 30.0 | 31.5 | 16.6 | 14.6 |
Payout ratio (%) | 100.0 | 118.6 | 125.5 | 100.6 | 102.8 |
Analyst Conclusions
Management guidance
There is no numerical guidance. The FY2026 annual report says:
-
recovery momentum continued, with "encouraging" April and May 2026;
-
the focus is on core Hong Kong services, selective multi-brand expansion and strategic opportunities;
-
cost discipline and a sustainable dividend policy will be maintained. [S1]
Bull case
-
Operating leverage on recovery. Costs have been reset: headcount −40% and leased area −20% since FY2024. If revenue simply stabilises at the H2 FY2026 run-rate of about HK$476m per half and grows modestly, the H2 FY2026 net margin of 17.6% could move back towards the historical 22–23%.
-
Valuation and yield. At about 9.4x P/E, 4.3x post-rent EV/EBITDA and an 11% yield, with HK$523m of cash and investments (about 31% of market cap), the market prices in continued decline. The largest listed HK peer, by contrast, is loss-making.
-
Competitive shake-out. Smaller operators are exiting, and EC Healthcare is losing money while Perfect Medical stays profitable. Oracle directly targets the Korea leakage.
Bear case
-
The leakage is structural. Revenue has fallen for two years, and outside-HK revenue for five. Shenzhen and Korean price points may cap Hong Kong pricing permanently.
-
Dividends exceed lease-adjusted cash generation. Cash fell from HK$656.8m to HK$294.9m over three years. The current ratio is now 1.06x and net current assets only HK$20.1m. A sub-100% payout or a dividend cut would remove the main support for the shares.
-
Governance and capital allocation. The company has 75% family control and a combined Chair/CEO. It granted a 50m-option award to the controller at the share-price trough. HK$228m (27% of total assets) is held in equities and ETFs rather than returned to shareholders or invested in the business. Minority shareholders bear these risks.
Catalysts and monitorables (next 12 months)
H1 FY2027 interim results (expected late Nov 2026): HK year-on-year revenue trend; interim DPS against EPS; cash balance.
Oracle: contribution and any disclosure of new-customer metrics.
Shenzhen M&A: execution, price and structure.
- Exercise of the 50m-option grant, and any further option schemes.
HK retail sales data: and outbound-travel statistics.
Supplier concentration: trend; any regulatory developments in HK or PRC aesthetics.
Investment-portfolio: marks and any reallocation.
Analyst verdict
Perfect Medical is a high-quality operator in a structurally challenged market.
On the evidence of FY2026, management can defend profitability under pressure. Revenue fell 14.7%, yet operating margin held at 22.1% and net margin improved to 18.6%. Over the same year, Hong Kong's largest listed peer lost more than HK$400m. The prepaid, debt-free model still converts profit into operating cash efficiently: OCF of HK$339.5m against net profit of HK$178.7m. Eleven consecutive years of 100%-plus payouts give the shares an unusual income profile, with a dividend yield of about 11%.
The investment case is not simply "cheap and profitable", however. The top line has fallen 31% from its peak because Hong Kong consumers have discovered cheaper substitutes across the border and in Korea. The company's own disclosures frame this as the "new normal". International expansion has repeatedly failed to diversify the business. The liquidity cushion that let the group over-distribute has shrunk:
-
cash is down 55% in three years;
-
the current ratio is 1.06x;
-
the current dividend therefore depends on earnings stabilising, not on the balance sheet.
Governance features further limit what minority investors can capture of the value: a combined Chair/CEO, family control, long-tenured INEDs, performance-free options and a sizeable discretionary equity portfolio.
Balance of evidence. The second-half FY2026 data points (year-on-year profit up 27.1%, revenue decline narrowing to 6.1%, closures halted) suggest the trough has passed. The modest multiple already discounts a lot.
Key test. The H1 FY2027 interim result needs to show stable Hong Kong revenue and an interim dividend covered by earnings without further cash drawdown. If it does, a re-rating towards 11–12x earnings is plausible. If it does not, the yield is at risk of being cut, and the low multiple would prove to be a value trap rather than an opportunity.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Age (AR 2026) | Background |
|---|---|---|---|---|
Dr. Au-Yeung Kong | Founder; Chairman & CEO; executive director; Nomination Committee member | 11 Mar 2011 (founded group 2003) | 54 | MBBS, CUHK (1995); registered medical practitioner in HK. Brother of the two other family directors. |
Ms. Au-Yeung Wai | Executive director (oversees daily operations; described as COO by aggregators); Nomination Committee member | 11 Mar 2011 (joined 2004) | 57 | BA Accountancy, CityU (1991); master's in business studies, University of Kent (1995) |
Ms. Au-Yeung Hung | Executive director (operational management of service centres) | 11 Mar 2011 (joined 2005) | 62 | BBA, University of Southern Queensland (1992) |
Mr. So Hin Lung | Executive director; CFO; Company Secretary | ED 28 Sep 2022 (joined Mar 2011) | 49 | Former Deloitte audit manager; EMBA, CUHK; MCF, PolyU; HKICPA member |
Ms. Hsu Wai Man, Helen | INED; Audit Committee chair | 5 Dec 2011 | 56 | Former Ernst & Young partner (18 years); FCPA (HK), AICPA. INED of several other listcos. |
Mr. Chi Chi Hung, Kenneth | INED; Remuneration Committee chair | 5 Dec 2011 | 57 | 30+ years in accounting and finance; FCCA |
Ms. Cho Yi Ping | INED; Nomination Committee chair | 14 Aug 2015 | 48 | Solicitor; partner at Wong & Tang Solicitors; LLB, HKU |
Mr. Chuk Sai Cheong Simon | INED | 1 Jul 2024 | 44 | Partner, Templewater (APAC mid-market buyouts); about 20 years in PE and investment banking; Columbia BA |
Governance Detail
| Data point | Detail | Source |
|---|---|---|
FY2026 key-management pay bands (8 people) | 4 at nil–HK$1m; 3 at HK$1–5m; 1 over HK$5m | S1 |
| — | Dr. Au-Yeung Kong HK$31.56m; Ms. Au-Yeung Wai HK$4.97m; Ms. Au-Yeung Hung HK$4.97m; Mr. So HK$0.92m | S15 |
Options granted 12 Dec 2023 | 1.256m each to the three family directors at HK$3.346; no performance targets | S3 |
Options granted 7 Jan 2025 | 1.256m each to the three family directors at HK$2.208; no performance targets | S2 |
Conditional grant (approved 18 Jun 2026) | 50,000,000 options to Dr. Au-Yeung Kong at HK$1.184 under the 2026 Share Option Scheme, about 4.0% of issued shares | S1 |
Board & Management Changes
| Date | Change |
|---|---|
28 Sep 2022 | CFO So Hin Lung appointed executive director |
1 Jul 2024 | Chuk Sai Cheong Simon appointed INED (fourth INED, to refresh long-tenured independence) |
28 Sep 2025 | So Hin Lung's new 3-year service contract begins |
23 Apr 2026 | Executive directors exit the Remuneration Committee |
18 Jun 2026 | 2021 option scheme terminated; 2026 scheme adopted |
Major Shareholders
| Holder | Shares | % of issued | Date | Source |
|---|---|---|---|---|
Dr. Au-Yeung Kong (direct, 114,834,747 shares, plus deemed interest via Sure Sino) | 942,003,768 plus options | 75.18 (incl. options) | 31 Mar 2025 | S2 |
Sure Sino Investments Ltd (family holding company), total | 827,169,021 | 65.85 | 31 Mar 2024 | S3 |
— of which held directly by Sure Sino | 459,739,481 | 36.60 | 31 Mar 2024 | S3 |
— of which Earlson Holdings Ltd | 208,306,511 | 16.58 | 31 Mar 2024 | S3 |
— of which Perfect Medical Charity Foundation Ltd | 159,123,029 | 12.67 | 31 Mar 2024 | S3 |
Mr. So Hin Lung | 140,000 | 0.01 | 31 Mar 2025 | S2 |
Free float (derived) | about 314m | about 25 | 2025 | derived |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Listing | Latest revenue | Positioning vs Perfect Medical |
|---|---|---|---|---|
EC Healthcare (醫思健康; formerly Union Medical Healthcare) | HK aesthetic medical, beauty and wellness; also medical, dental, veterinary | HKEX 2138 | FY2026 HK$3,770.2m total; aesthetic, beauty and wellness HK$1,322.9m; loss HK$412.9m [S17] | Larger, diversified, loss-making. Perfect Medical is far more profitable, but EC Healthcare's aesthetic segment alone is about 1.4x Perfect Medical's total revenue. |
DR REBORN (brand) | HK medical aesthetics chain | — | — | Direct HK chain competitor |
Beauty Farm Medical and Health Industry | PRC beauty and wellness chain | HKEX 2373 | — | Competes in PRC beauty and wellness |
So-Young International | PRC medical aesthetics platform and clinics | NASDAQ SY | — | Online channel and clinic competitor in the PRC |
Shenzhen medical aesthetic clinics (fragmented) | Cross-border substitutes for HK clients | Mostly private | Not applicable | Main source of share loss in FY2025–FY2026 [S1, S2] |
South Korean dermatology clinic chains (Seoul) | Medical tourism substitute | Private | Not applicable | Main source of share loss; Oracle partnership is the response [S2] |
Neo Derm (HK) | HK medical aesthetics | — | — | HK mid-to-high-end competitor |
Modern Beauty Salon (HK) | HK beauty services | — | — | Traditional beauty competitor |
Independent HK dermatology and aesthetic clinics | Doctor-led injectables and lasers | Private | Not applicable | Fragmented competition. Management notes smaller operators exiting the market in FY2026 [S1]. |
Australian and Singapore aesthetic chains | Local markets | Various | Not applicable | Local competitors in sub-scale overseas operations |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Perfect Medical (FY2026) | EC Healthcare (FY2026) |
|---|---|---|
Revenue (HKD Mn) | 962.3 | 3,770.2 |
Revenue growth (%) | -14.7 | -8.9 |
Net margin (%) | 18.6 | -11.0 |
Operating / EBITDA margin (%) | 22.1 / 27.9 | — |
Market cap (HKD Mn, about Aug 2026) | about 1650 | about 450 |



